Amarin Corp. PLC (AMRN) Short Interest Update
Amarin Corp. PLC (NASDAQ:AMRN) saw a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 5,761,520 shares, a decrease of 29.9% from the September 15th total of 8,215,239 shares. Based on an average daily trading volume, of 3,887,459 shares, the short-interest ratio is currently 1.5 days.
Amarin Corp. PLC (NASDAQ:AMRN) opened at 2.99 on Friday. Amarin Corp. PLC has a 52 week low of $1.24 and a 52 week high of $3.46. The company has a 50 day moving average price of $2.99 and a 200 day moving average price of $2.37. The stock’s market cap is $551.81 million.
Amarin Corp. PLC (NASDAQ:AMRN) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.06. The company earned $32.82 million during the quarter, compared to analyst estimates of $29.97 million. During the same quarter in the prior year, the company earned ($0.15) EPS. The business’s revenue was up 85.4% on a year-over-year basis. Analysts expect that Amarin Corp. PLC will post ($0.42) EPS for the current fiscal year.
A number of equities research analysts have issued reports on AMRN shares. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Amarin Corp. PLC in a research report on Monday, August 8th. Cantor Fitzgerald started coverage on Amarin Corp. PLC in a research report on Tuesday, October 4th. They set a “buy” rating and a $6.00 price objective on the stock. Jefferies Group restated a “buy” rating and set a $3.50 price objective on shares of Amarin Corp. PLC in a research report on Thursday, July 7th. Finally, Zacks Investment Research upgraded Amarin Corp. PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, July 6th.
Institutional investors have recently added to or reduced their stakes in the stock. Timber Hill LLC increased its position in Amarin Corp. PLC by 229.8% in the second quarter. Timber Hill LLC now owns 53,504 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 37,283 shares in the last quarter. KCG Holdings Inc. increased its position in Amarin Corp. PLC by 1.2% in the second quarter. KCG Holdings Inc. now owns 73,026 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 900 shares in the last quarter. Acadian Asset Management LLC bought a new position in Amarin Corp. PLC during the second quarter valued at about $210,000. State Street Corp increased its position in Amarin Corp. PLC by 2.4% in the second quarter. State Street Corp now owns 104,259 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 2,491 shares in the last quarter. Finally, ProShare Advisors LLC increased its position in Amarin Corp. PLC by 0.9% in the second quarter. ProShare Advisors LLC now owns 132,338 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 1,180 shares in the last quarter. Institutional investors own 20.74% of the company’s stock.
About Amarin Corp. PLC
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Corp. PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corp. PLC and related companies with MarketBeat.com's FREE daily email newsletter.